Singapore markets closed

IDEAYA Biosciences, Inc. (IDYA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
42.19+0.01 (+0.02%)
As of 10:22AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.15B
Enterprise value 2.63B
Trailing P/E N/A
Forward P/E 4.65
PEG ratio (5-yr expected) N/A
Price/sales (ttm)103.75
Price/book (mrq)5.08
Enterprise value/revenue 112.52
Enterprise value/EBITDA -20.18

Trading information

Stock price history

Beta (5Y monthly) 0.80
52-week change 3113.65%
S&P500 52-week change 322.38%
52-week high 347.74
52-week low 318.96
50-day moving average 342.83
200-day moving average 334.15

Share statistics

Avg vol (3-month) 3705.07k
Avg vol (10-day) 3768.85k
Shares outstanding 574.76M
Implied shares outstanding 674.76M
Float 873.72M
% held by insiders 11.13%
% held by institutions 1104.39%
Shares short (15 Apr 2024) 49.83M
Short ratio (15 Apr 2024) 414.7
Short % of float (15 Apr 2024) 414.92%
Short % of shares outstanding (15 Apr 2024) 413.15%
Shares short (prior month 15 Mar 2024) 48.82M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,068.77%

Management effectiveness

Return on assets (ttm)-16.20%
Return on equity (ttm)-23.28%

Income statement

Revenue (ttm)23.39M
Revenue per share (ttm)0.41
Quarterly revenue growth (yoy)-2.50%
Gross profit (ttm)N/A
EBITDA -131.95M
Net income avi to common (ttm)-112.96M
Diluted EPS (ttm)-1.96
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)525.11M
Total cash per share (mrq)7.04
Total debt (mrq)2.87M
Total debt/equity (mrq)0.46%
Current ratio (mrq)19.65
Book value per share (mrq)9.55

Cash flow statement

Operating cash flow (ttm)-115.22M
Levered free cash flow (ttm)-70.28M